康妇炎胶囊联合抗生素治疗对慢性盆腔炎患者临床疗效及炎症因子水平影响

发布时间：2018-04-09 07:47

本文选题：康妇炎胶囊　切入点：抗生素　出处：《中华中医药学刊》2017年02期

【摘要】：观察康妇炎胶囊联合抗生素治疗对慢性盆腔炎患者临床疗效及炎症因子水平影响,指导临床治疗与用药。方法:医院2015年1月—2016年3月妇科门诊及病房收治的慢性盆腔炎患者74例随机分为观察组和对照组,每组37例,对照组采用抗生素治疗,观察组采用康妇炎胶囊+抗生素治疗,两组患者均治疗14 d。治疗后观察两组患者临床疗效,记录治疗前后血清中IL~(-1)(白介素-1)、IL-2(白介素-2)浓度表达情况及不良反应发生情况。结果:治疗后,观察组患者总缓解率94.59%,对照组的总缓解率为86.49%,观察组总缓解率显著高于对照组,差异具有统计学意义(P0.05)。与治疗前比较,两组患者IL~(-1)表达水平均降低,IL-2表达均升高,差异具有统计学意义(均P0.05);治疗后组间比较,观察组患者IL~(-1)及IL-2改善幅度由于对照组,差异具有统计学意义(均P0.05)。观察组患者食欲不振、恶心、嗜睡及头晕发病率与对照组水平相当,差异不具有统计学意义(均P0.05)。治疗前后两组患者血常规、生化指标变化差异均无统计学意义(P0.05)。结论:对慢性盆腔炎患者在抗生素治疗基础上加用康妇炎胶囊能够提高临床疗效,调整致炎和抗炎的动态平衡,且安全可靠,值得临床推广使用。
[Abstract]:To observe the effect of Kangfuyan capsule combined with antibiotics on the clinical effect and inflammatory factor level of patients with chronic pelvic inflammatory disease.Methods: from January 2015 to March 2016, 74 patients with chronic pelvic inflammatory disease were randomly divided into observation group (n = 37) and control group (n = 37).The observation group was treated with Kangfuyan capsule antibiotics and the two groups were treated for 14 days.After treatment, the clinical efficacy of the two groups was observed, and the expression of IL-2in serum before and after treatment and the occurrence of adverse reactions were recorded.Results: after treatment, the total remission rate of the observation group was 94.59 and the total remission rate of the control group was 86.49. The total remission rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P 0.05).Compared with before treatment, the expression level of IL1 in the two groups was significantly lower than that before treatment (all P 0.05) and the improvement of IL-2 in the observation group was statistically significant because of the control group (all P 0.05).The incidence of anorexia, nausea, lethargy and dizziness in the observation group was similar to that in the control group (all P 0.05).There was no significant difference in blood routine and biochemical indexes between the two groups before and after treatment (P 0.05).Conclusion: the application of Kangfuyan capsule on the basis of antibiotic therapy in patients with chronic pelvic inflammatory disease can improve the clinical efficacy, adjust the dynamic balance between inflammation and anti-inflammation, and be safe and reliable.
【作者单位】：杭州市富阳区妇幼保健院妇产科;
【分类号】：R711.33

【相似文献】